How I treat older patients with AML-Reference-Cited by-同舟云学术

How I treat older patients with AML

Published:2000-09-01 Issue:5 Volume:96 Page:1670-1673
ISSN:1528-0020
Container-title:Blood
language:en
Short-container-title:

Author:

Estey Elihu H.¹

Affiliation:

1. From the Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference36 articles.

1. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission.;Brincker;Cancer Treat Rep.,1985

2. Prognostic factors in cancer clinical trials.;Estey;Clin Cancer Res.,1997

3. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest oncology group study.;Leith;Blood.,1997

4. A randomized placebo-contolled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).;Rowe;Blood.,1995

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients br;UHOD-ULUSLAR HEMATOL;2023

2. A cohesive look at leukemogenesis: The cohesin complex and other driving mutations in AML;Neoplasia;2021-03

3. miR-21-5p promotes cell proliferation by targeting BCL11B in Thp-1 cells;Oncology Letters;2020-12-15

4. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome;Annals of Hematology;2020-02-22